
Livanova (LIVN) Stock Forecast & Price Target
Livanova (LIVN) Analyst Ratings
Bulls say
LivaNova demonstrated notable financial improvement, with a year-over-year operating margin increase of 180 basis points, driven by gross margin expansion and effective management of selling, general, and administrative expenses. The company reported mid-single-digit revenue growth of 6.7% for 2024, supported by the anticipated launch of the Essenz heart-lung machine and expected organic growth of 7.0-8.0% in the Cardiopulmonary segment for 2025. Additionally, LivaNova's production capacity for oxygenators improved by 10% in 2024, with expectations for a further 10-15% increase in 2025, positioning the firm favorably as it prepares to capitalize on the recovery of elective procedures post-pandemic.
Bears say
LivaNova's recent financial performance shows signs of slowing growth, with neuromodulation sales increasing by only 1.0% to $137.6 million, significantly down from 8.8% growth in the previous quarter. The company's bear case scenario outlines potential revenue growth stagnating in the low single digits due to ongoing challenges in both the Neuromodulation and Cardiovascular segments, compounded by operating margin contraction and earnings that may fall below consensus estimates. Furthermore, while LivaNova's 2025 revenue guidance is slightly below expectations, its organic revenue growth has already shown a decline, dropping to 7% in the fourth quarter from 12% in the third quarter.
This aggregate rating is based on analysts' research of Livanova and is not a guaranteed prediction by Public.com or investment advice.
Livanova (LIVN) Analyst Forecast & Price Prediction
Start investing in Livanova (LIVN)
Order type
Buy in
Order amount
Est. shares
0 shares